Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
MELBOURNE, Australia, Aug. 16, 2022 - Opthea Limited (ASX:OPT; NASDAQ:OPT) announces that CEO Dr. Megan Baldwin will speak at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022. The presentation can be accessed on the Opthea website for 90 days starting at 7:00 AM ET (9:00 PM AET). Opthea is developing novel therapies for retinal diseases like wet AMD and DME, with its lead candidate OPT-302 currently in pivotal Phase 3 trials, aiming to enhance treatment efficacy against VEGF family inhibitions. Investments in biotechnology carry inherent risks.
- CEO Dr. Megan Baldwin presenting at a notable virtual conference, potentially increasing company visibility.
- OPT-302 is in pivotal Phase 3 clinical trials, indicating progress in drug development.
- Focus on treating unmet needs in retinal diseases, which could position Opthea favorably in the market.
- Biotechnology investments are highly speculative with inherent risks associated with drug development.
- A significant proportion of drugs fail clinical trials, which may affect future prospects.
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Chief Executive Officer Dr. Megan Baldwin will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place virtually on August 17, 2022.
The presentation will be made available at 7:00 AM ET (9:00 PM AET) and may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/.
About Opthea Limited
Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.
Inherent risks of Investment in Biotechnology Companies
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
Authorized for release to ASX by Megan Baldwin, CEO & Managing Director
Company & Media Enquiries:
| U.S.A. & International: | Australia: |
| Sam Martin | Rudi Michelson |
| Argot Partners | Monsoon Communications |
| Tel: +1 212-600-1902 | Tel: +61 (0) 3 9620 3333 |
| opthea@argotpartners.com |
Media:
Silvana Guerci-Lena
NorthStream Global Partners
Tel: +1 973-509-4671
silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com
FAQ
When is Dr. Megan Baldwin's presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference?
What is the focus of Opthea Limited's research?
What clinical stage is Opthea's lead product candidate, OPT-302, currently in?
Where can investors access the presentation by Opthea Limited?
What are the risks associated with investing in biotechnology companies like Opthea?
